###begin article-title 0
###xml 114 119 <span type="species:ncbi:10090">mouse</span>
Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 370 377 370 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 478 483 <span type="species:ncbi:10090">mouse</span>
###xml 501 505 <span type="species:ncbi:10090">mice</span>
###xml 545 549 <span type="species:ncbi:10090">mice</span>
###xml 570 574 <span type="species:ncbi:10090">mice</span>
###xml 618 622 <span type="species:ncbi:10090">mice</span>
Huntington disease (HD) is an adult onset neurodegenerative disorder caused by a polyglutamine expansion in the huntingtin (htt) protein. Htt function is essential for embryonic survival as well as normal function during the postnatal period. In addition to having roles in transcription and transport, recent evidence demonstrates that wild-type htt is neuroprotective in vivo. To determine whether treatment with wild-type htt would be beneficial in HD, we crossed the YAC128 mouse model of HD with mice that over-express wild-type htt (YAC18 mice) to generate YAC128 mice that over-express wild-type htt (YAC18/128 mice).
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 126 130 <span type="species:ncbi:10090">mice</span>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
###xml 210 214 <span type="species:ncbi:10090">mice</span>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
###xml 451 455 <span type="species:ncbi:10090">mice</span>
###xml 553 557 <span type="species:ncbi:10090">mice</span>
###xml 577 581 <span type="species:ncbi:10090">mice</span>
YAC18/128 mice were found to express mutant htt at the same level as YAC128 mice and wild-type htt at the same level as YAC18 mice. YAC18/128 mice show no significant behavioural improvement compared to YAC128 mice in the rotarod test of motor coordination or in an automated open field test. In the brain, YAC18/128 mice show no significant improvement in striatal volume, striatal neuronal numbers or striatal DARPP-32 expression compared to YAC128 mice. In contrast, striatal neuronal cross-sectional area showed significant improvement in YAC18/128 mice compared to YAC128 mice.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 110 114 <span type="species:ncbi:10090">mice</span>
While the over-expression of wild-type htt results in a mild improvement in striatal neuropathology in YAC128 mice, our findings suggest that treatment with wild-type htt may not be sufficient to ameliorate the symptoms of HD in this model.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 242 243 242 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 562 563 562 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 314 322 <span type="species:ncbi:9606">patients</span>
###xml 479 483 <span type="species:ncbi:10090">mice</span>
Huntington disease (HD) is an autosomal dominant disorder resulting from a trinucleotide CAG expansion in the HD gene. While the expression of mutant htt is sufficient to cause HD-like symptoms with normal expression levels of wild-type htt [1-3], recent data suggests that decreased levels of wild-type htt in HD patients may also contribute significantly to the pathogenesis of HD [4]. In support of this, we have recently demonstrated that the loss of wild-type htt in YAC128 mice significantly worsens motor performance, survival and striatal neuronal size [5].
###end p 9
###begin p 10
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 240 241 240 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 242 243 242 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 98 103 <span type="species:ncbi:10090">mouse</span>
###xml 314 318 <span type="species:ncbi:10090">mice</span>
Htt function is essential for development as mice homozygous for the targeted inactivation of the mouse HD gene are embryonic lethal [6-8]. Furthermore, decreasing htt levels by 50% or more from birth results in neurological abnormalities [7,9,10]. The expression of wild-type htt is also essential postnatally as mice expressing decreased levels of wild-type htt in the forebrain beginning at postnatal day 5 were shown to have a progressive neurological phenotype [11]. Clearly, decreased wild-type htt levels alone can lead to phenotypic abnormalities independent of mutant htt.
###end p 10
###begin p 11
###xml 149 158 149 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 487 496 487 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 497 499 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 533 541 533 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 673 674 673 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 675 677 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 791 793 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1001 1003 1001 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1004 1006 1004 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1198 1200 1198 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
As the functions of wild-type htt become more clear, it seems that one of the most critical functions for htt may be in promoting neuronal survival. In vitro studies have demonstrated that the over-expression of wild-type htt protects cells against various insults including 3-nitroproprionic acid, a toxin which damages the striatum and has been used to model HD [12]. It has also been shown that over-expression of wild-type htt can specifically protect against polyglutamine toxicity in vitro [13]. This finding has been extended in vivo where increased expression of wild-type htt eliminated apoptotic degeneration in the testis caused by the expression of mutant htt [5,14]. The mechanism by which htt protects neurons may be direct by sequestration of the pro-apoptotic protein HIP-1 [15] or indirectly mediated through htt's effect on expression and transport within the cell as htt has been shown to be involved in both the transcription and movement of the brain derived neurotrophic factor [16-18]. In contrast, fragments of mutant htt have been shown to also protect against some forms of injury (excitotoxicity) through a different mechanism, likely the induction of a stress response [19].
###end p 11
###begin p 12
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 166 174 166 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 524 526 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 671 673 671 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 258 262 <span type="species:ncbi:10090">mice</span>
###xml 292 297 <span type="species:ncbi:4932">yeast</span>
###xml 342 347 <span type="species:ncbi:9606">human</span>
###xml 436 440 <span type="species:ncbi:10090">mice</span>
###xml 546 550 <span type="species:ncbi:10090">mice</span>
In HD, there is evidence that striatal neurons die through excitotoxic mechanisms [20,21]. As such, we have previously examined the ability of htt to protect neurons in vivo against two different excitotoxic neurotoxins. For these experiments, we used YAC18 mice that over-express htt from a yeast artificial chromosome containing the entire human HD gene with 18 CAG repeats [22]. After intraperitoneal injection of kainic acid, YAC18 mice showed dramatically less neuronal loss in the hippocampus compared to WT controls [42]. Similarly, YAC18 mice showed significant, htt dose-dependent protection against lesions caused by intrastriatal injection of quinolinic acid [23].
###end p 12
###begin p 13
###xml 36 44 36 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 178 186 178 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 707 709 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 710 712 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 817 819 817 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 820 822 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 826 828 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 927 929 927 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 314 322 <span type="species:ncbi:9606">patients</span>
Based on the clear demonstration of in vivo protection against excitotoxic cell death in YAC18 mice and the general protective effect of wild-type htt that has been demonstrated in vitro, we designed this experiment to determine if the over-expression of wild-type htt would be beneficial in treating HD. Since HD patients have at least a 50% genetic reduction in wild-type htt levels (resulting from the presence of at least one copy of the mutant HD gene), it is plausible that this decrease in htt's neuroprotective function will make neurons more susceptible to the toxicity of mutant htt. A decrease in wild-type htt levels may also affect htt's role in transcription and transport within the cell [16-18,24]. In fact many of htt's assayable functions have been shown to be disrupted by polyglutamine expansion [12,16,17,23] and polyglutamine expansion also alters htt's ability to interact with its interacting proteins [24]. Thus, treatment of HD with wild-type htt may be beneficial by compensating for the loss of wild-type htt function and or through htt's general neuroprotective effect.
###end p 13
###begin p 14
###xml 112 113 112 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 39 44 <span type="species:ncbi:10090">mouse</span>
###xml 97 102 <span type="species:ncbi:9606">human</span>
###xml 125 129 <span type="species:ncbi:10090">mice</span>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 257 261 <span type="species:ncbi:10090">mice</span>
###xml 328 332 <span type="species:ncbi:10090">mice</span>
###xml 376 380 <span type="species:ncbi:10090">mice</span>
###xml 439 443 <span type="species:ncbi:10090">mice</span>
For this experiment we used the YAC128 mouse model of HD which recapitulates many aspects of the human disease [3,25]. These mice exhibit progressive motor dysfunction, cognitive impairment and selective neurodegeneration. YAC128 mice were crossed to YAC18 mice (which over-express full-length wild-type htt) to generate YAC128 mice that over-express wild-type htt (YAC18/128 mice). We show that over-expression of wild-type htt in YAC128 mice results in a mild improvement in striatal neuropathology but does not improve motor dysfunction.
###end p 14
###begin title 15
Results
###end title 15
###begin title 16
###xml 21 25 <span type="species:ncbi:10090">mice</span>
Generation of YAC128 mice that over-express wild-type huntingtin
###end title 16
###begin p 17
###xml 469 471 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 762 764 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 935 937 935 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 125 129 <span type="species:ncbi:10090">mice</span>
###xml 149 153 <span type="species:ncbi:10090">mice</span>
###xml 197 201 <span type="species:ncbi:10090">mice</span>
###xml 410 414 <span type="species:ncbi:10090">mice</span>
###xml 642 646 <span type="species:ncbi:10090">mice</span>
###xml 706 710 <span type="species:ncbi:10090">mice</span>
###xml 814 818 <span type="species:ncbi:10090">mice</span>
###xml 924 928 <span type="species:ncbi:10090">mice</span>
To determine whether wild-type htt could protect against mutant htt toxicity in the brain, we crossed YAC128 mice with YAC18 mice to generate YAC128 mice that over-express wild-type htt (YAC18/128 mice). In order to maximize the amount of neuroprotection imparted by over-expression of wild-type htt, we used the highest expressing YAC18 line (line 212) available. We have previously shown that YAC18 line 212 mice express wild-type htt at 2-3 times endogenous levels [22,23,26] and exhibit the greatest degree of neuroprotection against quinolinic acid toxicity of all the YAC18 lines [23]. To confirm the high expression of htt in line 212 mice, we examined total wild-type huntingtin in line 212 and WT mice by Western blotting with polyclonal bkp1 antibody [27]. As previously reported, we found that line 212 mice express wild-type htt at levels that are more than two times the level of wild-type htt expression in WT mice (Fig. 1A, (WT: 0.386 +/- 0.014 arbitrary units, YAC18: 0.942 +/- 0.056 arbitrary units, p = 0.02).
###end p 17
###begin p 18
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1029 1031 1029 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 122 126 <span type="species:ncbi:10090">mice</span>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
###xml 237 242 <span type="species:ncbi:9606">human</span>
###xml 295 300 <span type="species:ncbi:9606">human</span>
###xml 417 422 <span type="species:ncbi:10090">mouse</span>
###xml 427 432 <span type="species:ncbi:9606">human</span>
###xml 464 468 <span type="species:ncbi:10090">mice</span>
###xml 510 515 <span type="species:ncbi:10090">mouse</span>
###xml 527 532 <span type="species:ncbi:9606">human</span>
###xml 544 548 <span type="species:ncbi:10090">mice</span>
###xml 628 633 <span type="species:ncbi:9606">human</span>
###xml 657 661 <span type="species:ncbi:10090">mice</span>
###xml 708 712 <span type="species:ncbi:10090">mice</span>
###xml 717 722 <span type="species:ncbi:9606">human</span>
###xml 754 758 <span type="species:ncbi:10090">mice</span>
###xml 812 817 <span type="species:ncbi:9606">human</span>
###xml 914 918 <span type="species:ncbi:10090">mice</span>
After breeding YAC18 and YAC128 mice together, YAC18/128 mice were generated in equal proportions to WT, YAC18 and YAC128 mice indicating normal embryonic survival. Since the YAC transgenes used to generate YAC18 and YAC128 mice express human htt, we examined transgenic htt expression with the human specific htt antibody, HD650 (Fig. 1B; [3]). We also examined total htt expression using MAB2166 which detects both mouse and human htt (Fig. 1B). As expected, WT mice (non-transgenic FVB/N) express wild-type mouse htt and no human htt. YAC18 mice express increased levels of wild-type htt which are accounted for by increased human htt expression. YAC128 mice express wild-type htt at the same level as WT mice and human mutant htt. Finally, YAC18/128 mice express increased levels of wild-type htt and mutant human htt. Importantly, the level of mutant htt expression was equal between the YAC128 and YAC18/128 mice indicating that the over-expression of wild-type htt did not down-regulate the expression of mutant htt (Fig. 1C; YAC128: 3389 +/- 197 arbitrary units, YAC18/128: 3303 +/- 316 arbitrary units, p = 0.8; N = 3).
###end p 18
###begin title 19
###xml 82 86 <span type="species:ncbi:10090">mice</span>
Over-expression of wild-type huntingtin does not improve motor function in YAC128 mice
###end title 19
###begin p 20
###xml 253 260 253 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink">(3,36) </sub>
###xml 477 495 473 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">YAC128vsYAC18/128 </sup>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 379 383 <span type="species:ncbi:10090">mice</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
To examine the effect of wild-type htt on the motor dysfunction present in the YAC128 mice, we monitored motor coordination on the rotarod from 2 to 12 months of age. While ANOVA revealed an overall effect of genotype on rotarod performance (genotype: F(3,36) = 7.9, p < 0.001, N = 8 WT, 9 YAC128, 16 YAC18, 8 YAC18/128), there were no significant differences between the YAC128 mice and YAC18/128 at any time point (YAC128: 147 +/- 13 seconds, YAC18/128: 134 +/- 14 seconds, pYAC128vsYAC18/128 = 0.5, YAC18: 164 +/- 19 seconds). Both groups performed significantly worse than WT mice (WT: 227 +/- 15 seconds, p < 0.001).
###end p 20
###begin p 21
###xml 106 107 106 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 108 109 108 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 491 509 487 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink">YAC128vsYAC18/128 </sup>
###xml 627 645 617 635 <sup xmlns:xlink="http://www.w3.org/1999/xlink">YAC128vsYAC18/128 </sup>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 100 104 <span type="species:ncbi:10090">mice</span>
###xml 159 163 <span type="species:ncbi:10090">mice</span>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 312 316 <span type="species:ncbi:10090">mice</span>
###xml 382 386 <span type="species:ncbi:10090">mice</span>
###xml 406 410 <span type="species:ncbi:10090">mice</span>
###xml 820 824 <span type="species:ncbi:10090">mice</span>
We have previously reported early hyperactivity and late hypoactivity in YAC128 mice compared to WT mice [3,5]. As such, we compared the activity of YAC18/128 mice and YAC128 mice at 2 and 12 months of age to determine if wild-type htt expression could ameliorate the abnormal activity pattern present in YAC128 mice. We observed no significant improvement in activity in YAC18/128 mice compared to YAC128 mice (2 months - YAC128: 334 +/- 13 beam breaks, YAC18/128: 320 +/- 12 beam breaks, pYAC128vsYAC18/128 = 0.5, YAC18: 324 +/- 11 beam breaks; 12 months - YAC128: 274 +/- 19 beam breaks, YAC18/128: 289 +/- 15 beam breaks, pYAC128vsYAC18/128 = 0.5, YAC18: 277 +/- 11; N = 8 WT, 9 YAC128, 16 YAC18, 8 YAC18/128). Overall, increasing wild-type htt expression did not provide a significant behavioural benefit to YAC128 mice.
###end p 21
###begin p 22
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 187 191 <span type="species:ncbi:10090">mice</span>
###xml 286 290 <span type="species:ncbi:10090">mice</span>
###xml 363 367 <span type="species:ncbi:10090">mice</span>
While this study was not powered to demonstrate significant differences in survival, the number of YAC18/128 mice surviving to 12 months was similar to what we normally observe in YAC128 mice [Table 1; 12 month survival - WT males: 91%, YAC128 males: 73%, YAC18/128 males: 73% (8 of 11 mice), WT females: 90%, YAC128 females: 93%, YAC18/128 females: 100% (4 of 4 mice)].
###end p 22
###begin p 23
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 401 419 393 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink">YAC128vsYAC18/128 </sup>
###xml 575 593 559 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink">YAC128vsYAC18/128 </sup>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 695 699 <span type="species:ncbi:10090">mice</span>
###xml 738 742 <span type="species:ncbi:10090">mice</span>
###xml 810 814 <span type="species:ncbi:10090">mice</span>
Mice surviving to 12 months of age were sacrificed and we examined brain and testicular weight as these have been shown to be decreased in YAC128 mice [3,5]. In both cases, there was a significant difference between YAC128 and WT mice which was not improved by the over-expression of wild-type htt (Brain weight - WT: 403 +/- 7 mg, YAC18: 402 +/- 4 mg, YAC128: 384 +/- 4 mg, YAC18/128: 382 +/- 3 mg, pYAC128vsYAC18/128 = 0.6, N = 17 WT, 17 YAC128, 14 YAC18, 17 YAC18/128; Testis weight - WT: 164 +/- 5 mg, YAC18: 152 +/- 7 mg, YAC128: 142 +/- 5 mg, YAC18/128: 123 +/- 4 mg, pYAC128vsYAC18/128 = 0.01, N = 7 WT, 8 YAC128, 10 YAC18, 10 YAC18/128). Unexpectedly, the testicular weight in YAC18/128 mice was significantly less than in YAC128 mice and there was a trend towards decreased testicular weight in YAC18 mice compared to WT. This suggests the possibility that high levels of htt expression may be detrimental in the testis.
###end p 23
###begin title 24
###xml 105 109 <span type="species:ncbi:10090">mice</span>
Over-expression of wild-type huntingtin results in mild improvement in striatal neuropathology in YAC128 mice
###end title 24
###begin p 25
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 475 476 473 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 504 505 500 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 508 526 504 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink">YAC128vsYAC18/128 </sup>
###xml 556 557 550 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 638 640 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 854 856 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 934 952 918 936 <sup xmlns:xlink="http://www.w3.org/1999/xlink">YAC128vsYAC18/128 </sup>
###xml 1296 1298 1278 1280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2D</xref>
###xml 1323 1324 1303 1304 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1351 1352 1329 1330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1355 1373 1333 1351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">YAC128vsYAC18/128 </sup>
###xml 1403 1404 1379 1380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1570 1571 1544 1545 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 7 11 <span type="species:ncbi:10090">mice</span>
###xml 340 344 <span type="species:ncbi:10090">mice</span>
###xml 366 370 <span type="species:ncbi:10090">mice</span>
###xml 382 386 <span type="species:ncbi:10090">mice</span>
###xml 1102 1106 <span type="species:ncbi:10090">mice</span>
###xml 1155 1159 <span type="species:ncbi:10090">mice</span>
###xml 1220 1224 <span type="species:ncbi:10090">mice</span>
###xml 1513 1517 <span type="species:ncbi:10090">mice</span>
YAC128 mice demonstrate clear striatal neuropathology at 12 months of age with decreased striatal volume, striatal neuronal loss, striatal neuronal atrophy and decreased striatal DARPP-32 expression [3,28]. To determine whether the expression of wild-type htt could ameliorate these striatal phenotypes we examined the striata of YAC18/128 mice. Comparing YAC18/128 mice and YAC128 mice revealed no significant improvement in striatal volume (Fig. 2A; YAC128: 11.3 +/- 0.2 mm3, YAC18/128: 11.6 +/- 0.2 mm3, pYAC128vsYAC18/128 = 0.3, YAC18 = 12.5 +/- 0.3 mm3; N = 17 WT, 17 YAC128, 14 YAC18, 17 YAC18/128), striatal neuronal numbers (Fig. 2B; YAC128: 1.56 +/- 0.03 million neurons, YAC18/128: 1.59 +/- 0.03 million neurons, p = 0.4, YAC18: 1.64 +/- 0.03 million neurons; N = 17 WT, 17 YAC128, 14 YAC18, 17 YAC18/128) or striatal DARPP-32 expression (Fig. 2C; YAC128: 828 +/- 28 arbitrary units, YAC18/128: 868 +/- 22 arbitrary units, pYAC128vsYAC18/128 = 0.3, YAC18: 1012 +/- 19 arbitrary units; N = 10 WT, 12 YAC128, 10 YAC18, 8 YAC18/128) with increased wild-type htt expression. In each case, YAC128 mice showed significant abnormalities compared to WT mice. In contrast, increasing wild-type htt expression in YAC128 mice resulted in a significant reduction in striatal neuronal atrophy (Fig. 2D; YAC128: 96.2 +/- 1.6 um2, YAC18/128: 108 +/- 1.9 um2, pYAC128vsYAC18/128 < 0.001, YAC18: 110 +/- 1.7 um2; N = 17 WT, 17 YAC128, 14 YAC18, 17 YAC18/128) with the striatal neuronal cross-sectional area in YAC18/128 mice being almost restored to wild-type (WT: 110 +/- 3 um2, p = 0.6).
###end p 25
###begin title 26
Discussion
###end title 26
###begin p 27
###xml 236 241 <span type="species:ncbi:10090">mouse</span>
###xml 312 316 <span type="species:ncbi:10090">mice</span>
Based on recent work demonstrating a neuroprotective function of wild-type htt and suggestions that loss of wild-type htt function contributes to HD pathogenesis, we investigated the therapeutic potential of wild-type htt in the YAC128 mouse model of HD. We found that over-expression of wild-type htt in YAC128 mice resulted in a mild improvement in striatal neuropathology with no significant improvement in behavioural phenotypes.
###end p 27
###begin p 28
###xml 85 86 85 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 747 749 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 750 752 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 883 885 883 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 281 285 <span type="species:ncbi:10090">mice</span>
###xml 727 732 <span type="species:ncbi:10090">mouse</span>
The effect of over-expression of wild-type htt in YAC128 mice is summarized in table 2. A robust finding of this study was that over-expression of wild-type htt in YAC128 mice restored striatal neuronal size. Similarly, we have found that decreasing wild-type htt levels in YAC128 mice results in decreased neuronal size [5]. Combined, these results suggest that wild-type htt levels influence neuronal size and suggest that loss of wild-type htt may contribute to the striatal neuronal atrophy observed in HD. An alternate possibility is that striatal neuronal size is more responsive to mildly beneficial effects of treatments as this measure has been shown to exhibit the most dramatic improvements in therapeutic trials in mouse models of HD [29-31]. The effect of wild-type htt on neuronal size may be related to htt's ability to increase BDNF transcription [17] and transport [16] since BDNF promotes the survival and differentiation of striatal neurons.
###end p 28
###begin p 29
###xml 555 556 555 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 563 580 563 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">Additional file 1</xref>
###xml 239 243 <span type="species:ncbi:10090">mice</span>
###xml 390 394 <span type="species:ncbi:10090">mice</span>
In contrast to the significant improvement in striatal neuronal size, there was no significant effect of wild-type htt over-expression on open field activity, striatal volume, striatal neuronal counts or striatal DARPP-32 levels in YAC128 mice, despite a trend towards improvement. In parallel with these experiments we examined the effect of eliminating wild-type htt expression in YAC128 mice and found that there was a trend towards decreased striatal volume, striatal neuronal counts and striatal DARPP-32 expression which did not reach significance [5] (see Additional file 1 for summary). It is possible that the 12 month time point chosen to assess neuropathology in these experiments was too late in the disease process and that differences in severity were masked by a ceiling effect or that we have missed differences in the onset of striatal neuropathology.
###end p 29
###begin p 30
###xml 179 180 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 875 876 875 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
###xml 573 577 <span type="species:ncbi:10090">mice</span>
###xml 623 627 <span type="species:ncbi:10090">mice</span>
###xml 740 744 <span type="species:ncbi:10090">mice</span>
###xml 795 799 <span type="species:ncbi:10090">mice</span>
###xml 827 831 <span type="species:ncbi:10090">mice</span>
###xml 960 964 <span type="species:ncbi:10090">mice</span>
###xml 1080 1084 <span type="species:ncbi:10090">mice</span>
###xml 1280 1285 <span type="species:ncbi:9606">human</span>
###xml 1397 1402 <span type="species:ncbi:10090">mouse</span>
###xml 1439 1444 <span type="species:ncbi:10090">mouse</span>
In our previous study we observed a significant increase of both rotarod performance and survival when wild-type htt levels were increased in YAC128 -/- mice to wild-type levels [5]. In this experiment, we did not observe any further improvement in either rotarod performance or survival with the over-expression of wild-type htt suggesting that there may be ceiling effect for the amount that wild-type htt can improve these outcome measures. While this study did not have enough power to demonstrate a significant improvement in survival, the fact that the percentage of mice surviving to 12 months was similar to YAC128 mice suggests that the over-expression of wild-type huntingtin does not have a dramatic effect on survival in YAC128 mice. The survival deficit in the YAC128 and YAC18/128 mice were only observed in male mice thus confirming our previous observations [5]. Unexpectedly, we found that increasing wild-type huntingtin expression in YAC128 mice resulted in further decreases in testicular mass. Combined with a trend towards decreased testicular mass in YAC18 mice, this suggests the possibility that expression of htt beyond a certain threshold may result in testicular atrophy which is exacerbated by the presence of mutant htt. It is also possible that the human origin of the over-expressed htt contributes to the testicular phenotype. Unfortunately, we are not aware of a mouse model that over-expresses wild-type mouse htt at high levels that would permit testing of this hypothesis.
###end p 30
###begin p 31
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 298 299 298 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 34 39 <span type="species:ncbi:10090">mouse</span>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
###xml 292 296 <span type="species:ncbi:10090">mice</span>
###xml 318 322 <span type="species:ncbi:10090">mice</span>
###xml 375 383 <span type="species:ncbi:9606">patients</span>
###xml 467 471 <span type="species:ncbi:10090">mice</span>
###xml 533 537 <span type="species:ncbi:10090">mice</span>
###xml 675 680 <span type="species:ncbi:10090">mouse</span>
###xml 708 713 <span type="species:ncbi:10090">mouse</span>
###xml 801 805 <span type="species:ncbi:10090">mice</span>
In this study, we used the YAC128 mouse model of HD which transgenically expresses mutant huntingtin at approximately 75% of endogenous levels [3]. These mice have two intact copies of the wild-type HD gene and we have previously shown that they express wild-type htt at the same level as WT mice [5]. As such, YAC128 mice express higher levels of wild-type htt protein than patients with HD. The fact that the levels of wild-type htt are already increased in YAC128 mice may diminish the therapeutic benefit we observe in YAC18/128 mice by further over-expressing wild-type htt. To more directly assess the therapeutic benefit of wild-type htt in HD, one could over-express mouse wild-type htt in a knockin mouse model of HD to assess the effect of wild-type htt on early disease phenotypes in these mice.
###end p 31
###begin p 32
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 711 713 711 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 997 999 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1000 1002 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1051 1053 1051 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1070 1072 1070 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1146 1148 1146 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1251 1253 1251 1253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 107 112 <span type="species:ncbi:10090">mouse</span>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 377 385 <span type="species:ncbi:9606">patients</span>
###xml 482 486 <span type="species:ncbi:10090">mice</span>
###xml 560 564 <span type="species:ncbi:10090">mice</span>
###xml 605 609 <span type="species:ncbi:10090">mice</span>
###xml 674 678 <span type="species:ncbi:10090">mice</span>
###xml 1245 1249 <span type="species:ncbi:10090">mice</span>
###xml 1345 1353 <span type="species:ncbi:9606">patients</span>
The results of this study are congruent with comparisons of homozygous and heterozygous HD patients and HD mouse models which suggest that mutant htt has a greater influence on the disease phenotype than wild-type htt. Examination of disease severity in patients homozygous and heterozygous for mutations in the HD gene have reported either no difference or that homozygous HD patients are more severely affected [32-37]. Two independent studies have also examined the phenotype of mice that are homozygous for a targeted expansion of the HD gene (HD knock-in mice). In both cases, homozygous HD knock-in mice exhibited a more severe phenotype than heterozygous HD knock-in mice, but the differences were mild [38,39]. These studies suggest that mutant htt maintains many of the critical functions of wild-type htt as replacement of wild-type htt with mutant htt has only a mild effect on phenotype. However, it has been shown that polyglutamine expansion disrupts htt's neuroprotective function [12,23], at least part of htt's role in transcription [17] and transport [16], and also affects the interaction of htt with its interaction partners [24]. Since increasing mutant htt expression alone is known to result in a more severe phenotype in mice [40], it suggests that the increase in phenotypic severity between heterozygous and homozygous patients and animal models is mainly caused by the increase in mutant htt levels which is in line with our findings that increasing levels of wild-type htt has only a small impact on the disease phenotype.
###end p 32
###begin p 33
###xml 225 226 225 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 227 228 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 301 310 301 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 442 451 442 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 452 454 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 475 476 475 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 742 746 <span type="species:ncbi:10090">mice</span>
These findings are surprising given the importance of htt function and its demonstrated neuroprotective abilities. Htt is essential for embryonic development and decreases in htt expression alone lead to abnormal phenotypes [6-8,10,11,41]. Further, htt has been shown to protect cells from death both in vitro and in the testis and in the brain [12-14,23]. While htt has been shown to specifically protect against polyglutamine toxicity both in vitro [13] and in the testis [5,14], our findings here indicate a milder protective effect against mutant htt toxicity in the brain. Given that wild-type htt exhibits protection against excitotoxic neurotoxins [23], our finding that wild-type htt mildly improves striatal neuropathology in YAC128 mice is not inconsistent with excitotoxicity contributing to the pathogenesis of HD.
###end p 33
###begin title 34
Conclusion
###end title 34
###begin p 35
###xml 85 89 <span type="species:ncbi:10090">mice</span>
Overall, our results demonstrate that the over-expression of wild-type htt in YAC128 mice results in a mild improvement in striatal neuropathology. Based on the clear effect of htt over-expression on striatal neuronal size, it appears that htt function may be important in maintaining neuronal health. Despite the protective function of wild-type htt, our results suggest that mutant htt toxicity is primarily responsible for the pathognomic striatal neuropathology in HD and that treatment of HD with wild-type htt may not be sufficient to ameliorate the symptoms of the disease.
###end p 35
###begin title 36
Methods
###end title 36
###begin title 37
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 37
###begin p 38
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 72 77 <span type="species:ncbi:4932">yeast</span>
###xml 176 180 <span type="species:ncbi:10090">mice</span>
###xml 286 290 <span type="species:ncbi:10090">Mice</span>
###xml 371 375 <span type="species:ncbi:10090">Mice</span>
###xml 744 748 <span type="species:ncbi:10090">mice</span>
YAC18 and YAC128 mice that express human wild-type or mutant htt from a yeast artificial chromosome and wild-type littermates were used for these experiments [3,22]. For YAC18 mice, we used the high-expressing line 212 which expresses wild-type htt at 2-3 times endogenous levels [22]. Mice were maintained on the FVB/N (Charles River, Wilmington, MA) background strain. Mice were group housed with a normal light-dark cycle (lights on at 6:00 AM, lights off at 8:00 PM) in a clean facility and given free access to food and water. All experiments were carried out in accordance with protocols approved by the UBC Committee on Animal Care and the Canadian Council on Animal Care. The results shown are the combined results from male and female mice. We examined the data for both sexes separately and found no differences from the combined results.
###end p 38
###begin title 39
Behavioural analysis
###end title 39
###begin p 40
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 145 149 <span type="species:ncbi:10090">mice</span>
###xml 682 686 <span type="species:ncbi:10090">mice</span>
Motor coordination was assessed on an accelerating rotarod (UGO Basile, Comerio, Italy) as previously described [5]. After training at 2 months, mice were tested bimonthly from 2 to 12 months of age with a maximum score for each trial of 300 seconds. Open field activity was assessed in an automated open field apparatus (San Diego Instruments, San Diego, California). Activity was measured at 2 months and at 12 months during a ten minute open field trial. Activity was measured as the number of beam crosses in the trial. Clean cages were used for each trial. For behavioural assessment we used 8 WT (5 F, 3 M), 9 YAC128 (5 F, 4 M), 16 YAC18 (9 F, 7 M) and 8 YAC18/128 (3 F, 5 M) mice.
###end p 40
###begin title 41
Western blotting
###end title 41
###begin p 42
###xml 84 88 <span type="species:ncbi:10090">mice</span>
###xml 393 398 <span type="species:ncbi:9606">human</span>
###xml 453 458 <span type="species:ncbi:10090">mouse</span>
Protein levels were measured from homogenized whole brain lysates from a total of 3 mice per genotype. A low-bis acrylamide gel was run with 100 mug of total protein per sample for a total of 600 volt-hours. Proteins were transferred to a membrane at 24 volts for 1.5 hours. Blots were then probed with antibodies for either total htt (MAB2166, Chemicon, Temecula, California) or specifically human htt [HD650, (Slow et al., 2003a)] followed by an anti-mouse, peroxidase-conjugated secondary antibody before enhanced chemiluminescent detection. Protein levels were quantified using Quantity One software (Biorad, Hercules, CA).
###end p 42
###begin title 43
Neuropathology
###end title 43
###begin p 44
###xml 124 128 <span type="species:ncbi:10090">mice</span>
###xml 130 134 <span type="species:ncbi:10090">Mice</span>
Neuropathology was carried out on 17 WT (11 F, 6 M), 17 YAC128 (10 F, 7 M), 14 YAC18 (8 F, 6 M) and 17 YAC18/128 (8 F, 9 M) mice. Mice were perfused with 3% paraformaldehyde in phosphate buffered saline. Brains and testis were post-fixed in 3% paraformaldehyde for 24 hours and then equilibrated with PBS prior to weighing. Subsequently, brains were infiltrated with sucrose (25% in PBS), frozen and sectioned on a cryostat (Microm HM 500 M, Richard-Allan Scientific, Calamazoo, Michigan).
###end p 44
###begin p 45
###xml 202 207 <span type="species:ncbi:10090">mouse</span>
A series of 25 mum coronal sections spaced 200 mum apart were stained with NeuN primary antibody (1:100 dilution in 5% NGS, 0.1% T-X-100, PBS; Chemicon) overnight at room temperature, biotinylated anti-mouse secondary antibody (1:200 dilution in 1% NGS, 0.1% T-X-100, PBS) for 2 hours at room temperature and incubated in ABC reagent (ABC Elite kit, Vector) for 2 hours at room temperature before detection with metal-enhanced DAB solution (Pierce, Rockford, Illinois).
###end p 45
###begin p 46
###xml 917 922 <span type="species:ncbi:10090">mouse</span>
Striatal volume was determined using Stereoinvestigator software (Microbrightfield, Williston, Virginia). Briefly, the perimeter of the striatum was traced using a 2.5X objective in each section of the coronal series and the software calculated the volume of the entire structure. Subsequently, neuronal profiles in a 25 mum x 25 mum counting frame were counted with a 550 mum by 550 mum grid for all grids the fell within the outlined areas. The counts were then extrapolated to estimate the total number of neurons in the striatum. To determine neuronal cross-sectional areas, a single matched section from each animal was stained with an Alexa488-conjugated NeuN antibody (Chemicon). Mounted sections were analyzed using Stereoinvestigator to outline the perimeter of all clearly defined neurons within a 550 mum x 550 mum grid of 25 mum x 25 mum counting frames with the 100X objective. On average 32 neurons per mouse were assessed for a total of more than 450 neurons per genotype.
###end p 46
###begin p 47
###xml 67 73 <span type="species:ncbi:9986">rabbit</span>
###xml 192 196 <span type="species:ncbi:9925">goat</span>
###xml 202 208 <span type="species:ncbi:9986">rabbit</span>
For measurement of DARPP-32 expression, sections were stained with rabbit anti-DARPP-32 antibody (Chemicon AB 1656, 1:1000). After 3 washes with PBS, sections were incubated in Cy3-conjugated goat anti-rabbit antibody (1:500; Jackson ImmunoResearch Inc., West Grove, Pennsylvania). Pictures of mounted sections were taken using MetaMorph Imaging System (Molecular Devices, Downingtown, Pennsylvania) and the intensity of the fluorescent stain within the striatum was measured. 10 WT, 12 YAC128, 10 YAC18 and 8 YAC18/128 were used for this analysis.
###end p 47
###begin p 48
Immunohistochemistry for markers of neuronal health was performed as described above using the following antibodies: synaptophysin (1:100; BD Transduction Laboratories, Mississauga, Ontario), calbindin (1:2000; provided by Ken Bainbridge, University of British Columbia, Canada), EM48 (1:500; provided by Xiao-Jiang Li, Emory University, U.S.A) and 8-hydroxy-2-deoxyguanosine (1:500; Japan Institute for the Control of Aging, Fukuroi City, Japan).
###end p 48
###begin title 49
Statistical analysis
###end title 49
###begin p 50
###xml 217 221 <span type="species:ncbi:10090">mice</span>
Overall effects of genotype were determined by one way ANOVA. Repeated measures ANOVA analysis was used for analysis of differences in rotarod performance. The significance of differences between YAC128 and YAC18/128 mice was determined by either the Tukey post-hoc test following ANOVA or a student's t-test.
###end p 50
###begin title 51
Authors' contributions
###end title 51
###begin p 52
###xml 100 104 <span type="species:ncbi:10090">mice</span>
###xml 179 184 <span type="species:ncbi:9606">human</span>
JVR conceived the study, designed the experiment, completed the neuropathological assessment of the mice except for the striatal DARPP-32 levels, carried out the Western blot for human htt, prepared the figures for the manuscript and wrote the manuscript. JP carried out the behavioural analysis including rotarod and open field testing. ZM completed the western blot for total htt. MRH and BRL contributed to the conception and design of the experiment and were also involved in editing the manuscript. All of the authors have read and approved the final manuscript.
###end p 52
###begin title 53
Supplementary Material
###end title 53
###begin title 54
Additional File 1
###end title 54
###begin p 55
###xml 148 153 <span type="species:ncbi:10090">mouse</span>
Supplemental Table 1. This table summarizes the effect of increasing or decreasing wild-type huntingtin levels on phenotypic severity in the YAC128 mouse model of Huntington disease
###end p 55
###begin p 56
Click here for file
###end p 56
###begin title 57
Acknowledgements
###end title 57
###begin p 58
###xml 667 672 <span type="species:ncbi:9606">Human</span>
We would like to thank Daniel Rogers, Nagat Bissada, Kuljeet Vaid and Ge Lu for their technical assistance. This work was supported by grants from the Huntington's Disease Society of America, the High Q Foundation and the Huntington Society of Canada. JVR has been supported by the Canadian Institutes of Health Research, the Michael Smith Foundation for Health Research and the Huntington Society of Canada. BRL and MRH are supported by the Canadian Institutes of Health Research, the Huntington Society of Canada, the Hereditary Disease Foundation and the Canadian Genetic Diseases Network. MRH is a Killam University Professor and holds a Canada Research Chair in Human Genetics.
###end p 58
###begin article-title 59
###xml 6 11 <span type="species:ncbi:10090">mouse</span>
A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration
###end article-title 59
###begin article-title 60
###xml 60 75 <span type="species:ncbi:10090">transgenic mice</span>
Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA
###end article-title 60
###begin article-title 61
###xml 45 50 <span type="species:ncbi:10090">mouse</span>
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease
###end article-title 61
###begin article-title 62
Loss of normal huntingtin function: new developments in Huntington's disease research
###end article-title 62
###begin article-title 63
###xml 85 90 <span type="species:ncbi:10090">mouse</span>
Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease
###end article-title 63
###begin article-title 64
###xml 20 25 <span type="species:ncbi:10090">mouse</span>
Inactivation of the mouse Huntington's disease gene homolog Hdh
###end article-title 64
###begin article-title 65
Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes
###end article-title 65
###begin article-title 66
###xml 53 57 <span type="species:ncbi:10090">mice</span>
Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue
###end article-title 66
###begin article-title 67
###xml 87 91 <span type="species:ncbi:10090">mice</span>
Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene
###end article-title 67
###begin article-title 68
Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion
###end article-title 68
###begin article-title 69
###xml 102 106 <span type="species:ncbi:10090">mice</span>
Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice
###end article-title 69
###begin article-title 70
Wild-type huntingtin protects from apoptosis upstream of caspase-3
###end article-title 70
###begin article-title 71
Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease
###end article-title 71
###begin article-title 72
Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo
###end article-title 72
###begin article-title 73
Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain
###end article-title 73
###begin article-title 74
Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules
###end article-title 74
###begin article-title 75
Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease
###end article-title 75
###begin article-title 76
Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes
###end article-title 76
###begin article-title 77
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity
###end article-title 77
###begin article-title 78
Deranged neuronal calcium signaling and Huntington disease
###end article-title 78
###begin article-title 79
Biochemical abnormalities and excitotoxicity in Huntington's disease brain
###end article-title 79
###begin article-title 80
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 69 75 <span type="species:ncbi:10090">murine</span>
Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype
###end article-title 80
###begin article-title 81
Wild-type huntingtin protects neurons from excitotoxicity
###end article-title 81
###begin article-title 82
Huntingtin-protein interactions and the pathogenesis of Huntington's disease
###end article-title 82
###begin article-title 83
###xml 84 89 <span type="species:ncbi:10090">mouse</span>
Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease
###end article-title 83
###begin article-title 84
Body weight is modulated by levels of full-length Huntingtin
###end article-title 84
###begin article-title 85
Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme
###end article-title 85
###begin article-title 86
###xml 88 93 <span type="species:ncbi:10090">mouse</span>
Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease
###end article-title 86
###begin article-title 87
###xml 131 135 <span type="species:ncbi:10090">mice</span>
Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice
###end article-title 87
###begin article-title 88
###xml 88 93 <span type="species:ncbi:10090">mouse</span>
Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease
###end article-title 88
###begin article-title 89
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease
###end article-title 89
###begin article-title 90
Homozygosity in Huntington's disease
###end article-title 90
###begin article-title 91
A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats
###end article-title 91
###begin article-title 92
DNA analysis of Huntington's disease: five years of experience in Germany, Austria, and Switzerland
###end article-title 92
###begin article-title 93
Homozygote for Huntington disease
###end article-title 93
###begin article-title 94
Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course
###end article-title 94
###begin article-title 95
Homozygotes for Huntington's disease
###end article-title 95
###begin article-title 96
###xml 41 46 <span type="species:ncbi:10090">mouse</span>
Neurological abnormalities in a knock-in mouse model of Huntington's disease
###end article-title 96
###begin article-title 97
###xml 143 147 <span type="species:ncbi:10090">mice</span>
Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice
###end article-title 97
###begin article-title 98
###xml 94 99 <span type="species:ncbi:10090">mouse</span>
Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models
###end article-title 98
###begin article-title 99
###xml 66 70 <span type="species:ncbi:10090">mice</span>
The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin
###end article-title 99
###begin article-title 100
Huntingtin inhibits caspase-3 activation
###end article-title 100
###begin title 101
Figures and Tables
###end title 101
###begin p 102
###xml 0 39 0 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Huntingtin expression in YAC18/128 mice</bold>
###xml 104 107 104 107 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A. </bold>
###xml 399 402 395 398 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B. </bold>
###xml 1035 1038 1031 1034 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C. </bold>
###xml 35 39 <span type="species:ncbi:10090">mice</span>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
###xml 251 255 <span type="species:ncbi:10090">mice</span>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
###xml 416 421 <span type="species:ncbi:9606">human</span>
###xml 517 522 <span type="species:ncbi:9606">human</span>
###xml 635 639 <span type="species:ncbi:10090">mice</span>
###xml 709 713 <span type="species:ncbi:10090">mice</span>
###xml 792 796 <span type="species:ncbi:10090">mice</span>
###xml 808 813 <span type="species:ncbi:9606">human</span>
###xml 825 829 <span type="species:ncbi:10090">mice</span>
###xml 853 858 <span type="species:ncbi:9606">human</span>
###xml 874 878 <span type="species:ncbi:10090">mice</span>
###xml 899 904 <span type="species:ncbi:9606">human</span>
###xml 981 985 <span type="species:ncbi:10090">mice</span>
###xml 1098 1102 <span type="species:ncbi:10090">mice</span>
###xml 1150 1154 <span type="species:ncbi:10090">mice</span>
###xml 1251 1255 <span type="species:ncbi:10090">mice</span>
Huntingtin expression in YAC18/128 mice. YAC18 and YAC128 mice were crossed to generate YAC18/128 mice. A. To confirm high levels of htt over-expression in YAC18, line 212 mice we performed Western blots on whole brain lysates. We found that line 212 mice have 2.4 times the levels of wild-type htt as WT mice (WT: 0.386 +/- 0.014 arbitrary units, YAC18: 0.942 +/- 0.056 arbitrary units, p = 0.02). B. Total htt and human htt levels were assessed by Western blotting with MAB2166 and HD650 antibody respectively. The human specific HD650 antibody was used to detect htt expressed from the YAC transgenes in YAC18, YAC128 and YAC18/128 mice. Western blots performed with HD650 antibody indicate that YAC18/128 mice express both wild-type htt and mutant htt from YAC transgenes. As expected WT mice express no human htt, YAC18 mice express only wild-type human htt and YAC128 mice express only mutant human htt. Examination of total htt levels with MAB2166 antibody reveals that all mice express similar levels endogenous wild-type htt. C. Quantification of protein expression reveals that YAC18/128 mice express mutant htt at the same level as YAC128 mice (YAC128: 3389 +/- 197 arbitrary units, YAC18/128: 3303 +/- 316 arbitrary units, p = 0.8). N = 3 mice per group. Error bars indicate standard error of the mean. A.U. = arbitrary units.
###end p 102
###begin p 103
###xml 0 103 0 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Over-expression of wild-type htt results in mild improvements in striatal neuropathology in YAC128 mice</bold>
###xml 274 281 274 281 <bold xmlns:xlink="http://www.w3.org/1999/xlink">panel A</bold>
###xml 306 307 304 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 335 336 331 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 374 381 370 377 <bold xmlns:xlink="http://www.w3.org/1999/xlink">panel B</bold>
###xml 506 513 498 505 <bold xmlns:xlink="http://www.w3.org/1999/xlink">panel C</bold>
###xml 727 734 715 722 <bold xmlns:xlink="http://www.w3.org/1999/xlink">panel D</bold>
###xml 759 760 745 746 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 787 788 771 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 168 172 <span type="species:ncbi:10090">mice</span>
###xml 835 839 <span type="species:ncbi:10090">mice</span>
###xml 882 886 <span type="species:ncbi:10090">mice</span>
Over-expression of wild-type htt results in mild improvements in striatal neuropathology in YAC128 mice. Comparison of striatal phenotypes between YAC128 and YAC18/128 mice revealed that over-expression of wild-type htt resulted in no significant change in striatal volume (panel A: YAC128: 11.3 +/- 0.2 mm2, YAC18/128: 11.6 +/- 0.2 mm2, p = 0.3), striatal neuronal counts (panel B: YAC128: 1.56 +/- 0.03 million neurons, YAC18/128: 1.59 +/- 0.03 million neurons, p = 0.4) or striatal DARPP-32 expression (panel C: YAC128: 828 +/- 28 arbitrary units, YAC18/128: 868 +/- 22 arbitrary units, p = 0.3). In contrast, over-expression of wild-type htt resulted in a significant improvement in striatal neuronal cross-sectional area (panel D: YAC128: 96.2 +/- 1.6 um2, YAC18/128: 108 +/- 1.9 um2, p < 0.001). For each outcome measure, YAC128 mice show a significant deficit compared to WT mice. N = 17 WT, 17 YAC128, 14 YAC18, 17 YAC18/128 except for striatal DARPP-32 expression where N = 10 WT, 12 YAC128, 10 YAC18, 8 YAC18/128. Error bars show standard error of the mean. ** p < 0.01. *** p < 0.001.
###end p 103
###begin p 104
###xml 71 75 <span type="species:ncbi:10090">mice</span>
Effect of modulating wild-type huntingtin levels on survival in YAC128 mice.
###end p 104
###begin p 105
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 63 67 <span type="species:ncbi:10090">mice</span>
YAC128-/- mice express mutant htt and no wild-type htt. YAC128 mice express mutant htt and 2 copies of wild-type htt. YAC18/128 express mutant htt and increased levels of wild-type htt.
###end p 105
###begin p 106
###xml 86 91 <span type="species:ncbi:10090">mouse</span>
Effect of over-expression of wild-type huntingtin on HD-like phenotypes in the YAC128 mouse model of HD.
###end p 106

